NCT00102778

GW873140 In Combination With Kaletra In HIV Infected Subjects

A Phase IIb, 96 Week, Randomized, Open-label Multicenter, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, PK and Antiviral Effect of Different Doses and Regimens of GW873140 in Combination With Kaletra (Lopinavir and Ritonavir) in HIV-1 Infected Antiretroviral Therapy naïve Subjects

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 175 (planned)
• Sponsor: ViiV Healthcare · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Kaletra in HIV infected, untreated subjects.

Detailed description

A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regimens of GW873140 in combination with Kaletra (lopinavir and ritonavir) in HIV-1 infected antiretroviral therapy naive subjects

Conditions

• Infection, Human Immunodeficiency Virus I
• HIV Infection

Interventions

Type	Name	Description
DRUG	GW873140
DRUG	Kaletra (lopinavir/ritonavir)

Timeline

• Start date: 2004-12-01
• Primary completion: 2007-09-01
• Completion: 2007-09-01
• First posted: 2005-02-02
• Last updated: 2017-05-30

Locations

70 sites across 10 countries: United States, Canada, Denmark, France, Germany, Italy, Netherlands, Portugal, Spain, United Kingdom